These efforts will be crucial for understanding the full scope of factors affecting the prevalence of ALK alterations, which will lead to addressing the disparities seen in various racial/ethnic groups and improving treatment outcomes for those with ALK+ NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.